Accelerated discovery of thermostable mRNA-lipid nanoparticle vaccines using data-efficient AI.
AI-driven framework AGENT rapidly identified thermostable mRNA-LNP vaccine formulations, achieving 100% bioactivity after 2 months at 37°C in just six iterations.
- Why it matters: The instability of mRNA-LNP vaccines limits their global distribution due to cold storage requirements, hindering widespread access and application.
- What they did: Researchers developed AGENT, an AI-based approach combining high-throughput experiments and Bayesian optimization, to efficiently discover stable formulations within one month.
- The result: The stabilized vaccines maintained full bioactivity at elevated temperatures and elicited immune responses comparable to fresh vaccines in animal models, enabling broader vaccine deployment.